UnitedHealth (UNH) is under scrutiny for using aggressive tactics to maximize Medicare Advantage payments, leading to a 40% increase in stock value. The Senate found that UNH’s risk scores exceed industry benchmarks, resulting in $643 more in government spending per member annually. Despite trading at a discount, UNH faces multiple challenges, including a CEO change and regulatory inquiries. Analysts maintain a “Moderate Buy” rating with a target price of $397, offering a potential 20% upside. UNH also offers a healthy dividend yield of 2.67%.

Read more at Barchart: UnitedHealth Faces New Medicare Accusations. What Does That Mean for UNH Stock?